Experimental cocktail takes on toughest pancreatic cancer
NCT ID NCT07348107
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether adding ATRA, SDK002, and an immunotherapy drug to standard chemotherapy is safe for people with advanced pancreatic cancer that cannot be removed by surgery. Ten participants will receive all five drugs together. The study will also track how long they live without the cancer growing. Because it is a phase 1 trial, safety is the main focus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATRA (all-trans retinoic acid), SDK002 (arsenic trioxide), gemcitabine, nab-paclitaxel, and tislelizumab
What this could lead to
If this combination proves safe, it could point toward a new treatment option for advanced pancreatic cancer that may help patients live longer.
What could go wrong
This is a very early phase 1 study with only 10 people, so the main goal is safety, not effectiveness. The combination may cause serious side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Verspeeten Family Cancer Centre
London, Ontario, N6A 5W9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••